Zydus to Enter Global Biologics CDMO Business Plans

New Jersey, United States & Ahmedabad, Gujarat, India – Business Wire India
Zydus Lifesciences Ltd. (including its subsidiaries/affiliates, hereafter referred to as 'Zydus) today announced its entry into the global biologics contract development and manufacturing organization (CDMO) business through its plan to acquire Agenus Inc.'s (Nasdaq: AGEN) U.S.-based biologics CMC facilities. This acquisition marks Zydus' strategic investment in U.S.-based manufacturing for biologics thereby adding a sustainable growth driver for the group. Agenus Inc. is a clinical-stage immuno-oncology company committed to developing immune therapies that effectively combat cancer. Under the terms of the agreement, Zydus will acquire two state-of-the-art biologics manufacturing facilities from Agenus in Emeryville and Berkeley, California (US) for an upfront consideration of US$75 million and contingent payment of US$50 million to be paid over three years subject to achievement of certain revenue milestone. This acquisition provides Zydus immediate access to advanced biologics manufacturing capabilities and establishes a key presence in California, a leading global biotechnology hub. This strategic move enables Zydus to leverage supply chain dynamics and a favourable geopolitical environment to expand its reach in the U.S. and globally. With this acquisition Zydus will now become a one stop solution provider across the entire development spectrum of biologics, right from pre-clinical to toxicology studies, clinical development and now manufacturing.Zydus' CDMO business will operate as an independent entity and will house the acquired manufacturing capabilities. The facilities come with an experienced professional team with strong capabilities and requisite industry expertise to deliver high-quality biologics development and manufacturing services to global biotech and pharmaceutical companies. As a part of transaction Zydus will become an exclusive contract manufacturer for Agenus and will provide manufacturing services for clinical and commercial supply of two identified Phase-3 ready immuno-oncology products, Botensilimab (BOT) and Balstilimab (BAL). Zydus will also have first right of negotiation to manufacture any of the future pipeline products developed by Agenus. Zydus intends to further expand the team and help create new jobs in the region and contribute to the local economy.Speaking on the development, Dr. Sharvil Patel, Managing Director, Zydus Lifesciences Ltd. said, "The acquisition will give Zydus a strategic foothold in the U.S. for biologics manufacturing in the global hub for biotech innovation, California. It will enhance our ability to partner with innovation-centric entities, advancing new products and prioritizing patient-centric solutions. This move strengthens our long-term biologics vision and positions us to better serve the evolving needs of the global biopharmaceutical industry."
The global biologics CDMO market is experiencing significant growth, driven by the increasing complexity of therapies, the rise of biologics in clinical pipelines, and a growing number of emerging biotech companies lacking internal manufacturing capabilities. According to market.us, the Global Biologics CDMO Market Size is expected to be worth around US$ 84.9 Billion by 2034, growing at a CAGR of 15.7% between 2025 to 2034. As demand surges for reliable, agile, and scalable partners, Zydus' entry into this space positions it to tap into significant long-term growth opportunities and support innovation across the global biopharmaceutical landscape.
About Zydus
Zydus Lifesciences Ltd. with an overarching purpose of empowering people with freedom to live healthier and more fulfilled lives, is an innovative, global lifesciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies. The group employs 27,000 people worldwide, including 1,400 scientists engaged in R&D, and is driven by its mission to unlock new possibilities in lifesciences through quality healthcare solutions that impact lives. The group aspires to transform lives through path-breaking discoveries. Over the last decade, Zydus has introduced several innovative, first-in-class products in the market for treating unmet healthcare needs with vaccines, therapeutics, biologicals and biosimilars. For more details visit: www.zyduslife.com.
About Agenus
Agenus Inc. is a clinical-stage immuno-oncology company committed to developing immune therapies that effectively combat cancer. Leveraging proprietary scientific platforms, the company's pipeline includes multiple checkpoint antibody candidates, vaccines, and cell therapies. Headquartered in Lexington, MA, Agenus operates globally, driving innovations to bring better cancer treatments to patients. For more details visit: www.agenusbio.com.
Forward-Looking Statements:
This press release contains forward-looking statements. Such forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected. These risks and uncertainties include, but are not limited to, the successful integration of the acquired business, market conditions, and other factors.
Sujatha Rajesh (Media Relations), Zydus Lifesciences Limited, sujatha.rajesh@zyduslife.com, +91-9974051180
Arvind Bothra (Investor Relations), Zydus Lifesciences Limited, arvind.bothra@zyduslife.com, +91-7045656895

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

Economic Times

7 hours ago

• Economic Times

US stocks open higher with Trump's Middle East decision in focus

U.S. stocks are drifting higher on Friday in their return to trading following the Juneteenth holiday. ADVERTISEMENT The S&P 500 was up 0.4% in early trading and adding to its modest gain for the week. The Dow Jones Industrial Average was up 162 points, or 0.4%, as of 9:35 am. Eastern time, and the Nasdaq composite was 0.6% higher. Treasury yields were also edging higher in the bond market after President Donald Trump said he will decide within two weeks whether the U.S. military will get directly involved in Israel's fighting with Iran. The window offers the possibility of a negotiated settlement over Iran's nuclear program that could avoid increased fighting. The conflict has sent oil prices yo-yoing because of rising and ebbing fears that it could disrupt the global flow of crude. Iran is a major producer of oil and also sits on the narrow Strait of Hormuz, through which much of the world's crude passes. On Wall Street, Kroger jumped 6.8% to help lead the market after the grocer reported a better profit for the latest quarter than Wall Street had forecast. It also raised its forecast for an underlying measure of revenue for the full year. Chief Financial Officer David Kennerley said it's seeing positive momentum, but it's still seeing an uncertain overall economic environment. CarMax rose 4.6% after the auto dealer reported a stronger profit for the latest quarter than analysts expected. The company said it sold nearly 6% more used autos during the quarter than it did a year earlier. ADVERTISEMENT On the losing end of Wall Street was Smith & Wesson Brands, the maker of guns. It tumbled 15.3% after reporting profit and revenue for the latest quarter that fell just shy of analysts' Financial Officer Deana McPherson said 'persistent inflation, high interest rates, and uncertainty caused by tariff concerns' have been hurting sales for firearms, and the company expects demand in its upcoming fiscal year to be similar to this past year's, depending on how inflation and Trump's tariffs play out. ADVERTISEMENT A spate of companies has been adjusting or even withdrawing their financial forecasts for the year because of all the uncertainty that tariffs are creating for their customers and for their suppliers. Everyone is waiting to see how big the tariffs will ultimately not just corporate America. The Federal Reserve has been keeping its main interest rate on hold this year, with its latest such decision coming earlier this week, because it's waiting to see exactly by how much tariffs will grind down on the economy and push up inflation. ADVERTISEMENT In the bond market, Treasury yields edged higher. The yield on the 10-year Treasury rose to 4.41% from 4.38% late Wednesday. The two-year yield, which more closely tracks expectations for what the Fed will do, was holding at 3.94%.In stock markets abroad, indexes rose across much of Europe after finishing mixed in Asia. ADVERTISEMENT Tokyo's Nikkei 225 index edged 0.2% lower after Japan reported that its core inflation rate, excluding volatile food prices, rose to 3.7% in May, adding to challenges for Prime Minister Shigeru Ishiba's government and the central bank. (You can now subscribe to our ETMarkets WhatsApp channel)

Business Standard

8 hours ago

• Business Standard

MakeMyTrip raises $3.1 bn in APAC's biggest equity-bond deal since 2022

MakeMyTrip raises $3.1 billion via equity and convertible notes to reduce stake below 20 per cent, marking APAC's largest concurrent offering since 2022 MakeMyTrip has raised $3.1 billion through equity and bond offerings, marking the Asia-Pacific region's largest concurrent offering of equity follow-on and convertible notes since 2022, Kamal Yadav, head of investment banking at Morgan Stanley, said in a LinkedIn post on Friday. 'On June 17, 2025, after the close, MakeMyTrip priced a $3.1 billion concurrent registered primary equity follow-on and 144A convertible bond (post-shoe). The primary equity follow-on offering of 18,400,000 ordinary equity shares was priced at $90 per share. The five-year convertible senior notes offering, at 0 per cent coupon and 35.0 per cent conversion premium, together represent APAC's largest concurrent offering of equity follow-on and convertible notes since 2022,' Yadav wrote. The last major fundraise by an Indian internet company was Paytm's $2.5 billion initial public offering in 2021. Proceeds from the fundraise will be used to buy back stake held by Group Ltd, reducing the Chinese company's holding to under 20 per cent from the current 45.34 per cent. will continue to remain the largest minority shareholder in the company. The move comes amid allegations by founder Nishant Pitti that five out of 10 directors on the company's board had ties with China—claims that the Nasdaq-listed company dismissed as 'malicious and motivated'. MakeMyTrip did not respond to queries from Business Standard as of Friday evening. The company is yet to issue an official statement on the closure of the deal. MakeMyTrip had initially planned to offer 14 million new shares to raise $1.4 billion and zero-coupon convertible bonds worth $1.25 billion. It later increased the new share offering to 18.4 million shares, priced at $90—slightly lower than the $91.49 closing price on June 17.

Time of India

9 hours ago

• Time of India

US stock market today: Wall Street rises as investors monitor Middle East tension; CarMax jumps on earnings, oil and yields climb

US stocks gained ground on Friday as Wall Street reopened after the Juneteenth holiday, with investors balancing solid earnings from CarMax against rising geopolitical uncertainty in the Middle East. The S&P 500 rose 0.4% to extend its weekly gain, while the Dow Jones Industrial Average added 159 points and the Nasdaq composite climbed 0.6% at initial minutes of trading. Used-car retailer CarMax was among the session's top performers after reporting stronger-than-expected profits. According to the Associated Press, Treasury yields also edged higher after President Donald Trump said he would decide within two weeks whether the US military will join the Israel-Iran conflict. The news has kept traders on edge, with crude oil prices continuing to rise amid concerns about potential disruptions in global supply. US benchmark crude added 52 cents to $75.66 a barrel, while Brent crude, the international standard, climbed 31 cents to $77.01. Iran is a major oil producer and controls the strategic Strait of Hormuz, through which a large portion of global crude flows. "The stock market's risk premium isn't just rising — it's recalibrating for a world where every macro lever now doubles as a tripwire," said Stephen Innes, managing partner at SPI Asset Management, noting that markets are pricing in the uncertainty of Trump's next move. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Un ingreso adicional para ecuatorianos: invierte en Amazon CFD. InvestIQ Solicita ahora Undo In global markets, Europe saw a broad rally. The FTSE 100 in London gained 0.4%, Paris' CAC-40 rose 0.6%, and Germany's DAX added 0.9%. Meanwhile, performance across Asia was mixed: Hong Kong's Hang Seng gained 1.3% and South Korea's Kospi rose 1.5%, while Japan's Nikkei edged down 0.2% and Shanghai's Composite Index slipped 0.2%. Earlier, Japan reported that core inflation climbed to 3.7% in May, exceeding expectations and adding pressure on the Bank of Japan, already contending with Trump's tariffs. 'For now, it's more concerned about the risk that US trade policies could break the virtuous circle of wage growth and inflation," said Min Joo Kang, economist at ING. The Bank of England also held its main interest rate at 4.25% on Thursday, citing risks of a broader regional escalation. In currency markets, the US dollar slipped to 145.37 yen, and the euro rose to $1.1516. Stay informed with the latest business news, updates on bank holidays and public holidays . AI Masterclass for Students. Upskill Young Ones Today!– Join Now